Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo1
Safety and tolerability of the higher dose of Wegovy® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg)1
The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity
Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1
'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.'
STEP UP co-primary endpoints at 72 weeks*1: semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4%5% or more weight loss 93.2% 92.5% 35.7%When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo.
'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.'
In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1
Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved.
STEP UP selected confirmatory secondary endpoints at 72 weeks*1: semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9%25% or more weight loss 33.2% 16.7% 0%
* Based on the trial product estimand: treatment effect if all people adhered to treatment.
About the STEP UP trialsNovo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes.
The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively.
The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss.
About Wegovy®Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis.
In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media:
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors:
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com
Sina Meyer +45 3079 6656 azey@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com
References
Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17.
Attachment
PR250621-ADA-STEP-UP
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support
Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings, and promote healthy weight loss management using vegan-friendly ingredients. nixol New York City, June 21, 2025 (GLOBE NEWSWIRE) --Nixol, a plant-powered metabolic support supplement, is now available to individuals across the United Kingdom. Designed to help individuals struggling with weight control and sluggish metabolism, Nixol Capsules offer a science-informed approach to supporting natural fat-burning processes and curbing unnecessary cravings—without extreme diets or synthetic additives. With more UK residents focusing on sustainable wellness, Nixol enters the market at a time when natural health solutions are in growing demand. These once-daily vegan capsules aim to provide convenient support for those on their journey toward a more energized and balanced lifestyle. Visit Official Website Addressing a Modern Wellness Challenge In today's fast-paced world, many people face common roadblocks to maintaining a healthy weight loss—slowed metabolism, irregular cravings, fatigue, and a lack of time to commit to complicated regimens. Nixol was developed with these challenges in mind. Its formula blends carefully selected ingredients believed to support metabolic efficiency and digestive health, all in an easy-to-take format that fits seamlessly into daily routines. Unlike solutions that rely on synthetic stimulants or temporary fads, Nixol takes a gentler, more sustainable route. It aims to support the body's own natural processes over time, helping individuals feel more in control of their eating habits, energy levels, and overall wellness goals. What Makes Nixol Different? Many products make bold promises—but Nixol's philosophy centers around realistic, natural progress. Here's how Nixol stands out: ✅ Vegan-Friendly Capsules: Free from gelatin, dairy, soy, and gluten. ✅ Non-GMO Ingredients: Manufactured with quality standards in mind. ✅ Once-Daily Dosage: Simplifies wellness routines with zero guesswork. ✅ No Harsh Stimulants: Gentle on the system while supporting energy. Rather than offering instant results or dramatic weight fluctuations, Nixol is built to be a long-term companion in a person's journey toward better health. Visit Official Website To get More InformationThe Power Behind the Nixol Formula Each serving of Nixol contains a thoughtfully selected blend of natural ingredients—each with potential benefits tied to metabolism, digestion, or appetite support. Key Ingredients Include: Apple Cider Vinegar Extract – 100 mg: Traditionally used for its potential to support digestion and appetite regulation. It's a popular natural aid for those trying to manage portion sizes and sugar cravings. Guarana Extract – 100 mg: A natural source of caffeine, guarana may help promote energy and alertness without the crash. It also contributes to thermogenic processes that can aid fat metabolism. Inulin Powder from Jerusalem Artichoke – 100 mg: A prebiotic fiber that nourishes beneficial gut bacteria. Inulin may support smoother digestion and better nutrient absorption. L-Glutamine – 50 mg: An amino acid that supports gut lining health and may play a role in reducing sugar cravings and supporting energy levels. L-Leucine – 50 mg: Known to assist in muscle maintenance during calorie restriction, leucine helps support lean body mass and recovery. Zinc – 14 mg (140% DV): Essential for hormone regulation, immune health, and metabolic processes. Zinc also plays a role in appetite and insulin sensitivity. Chromium – 40 mcg (100% DV): Linked to blood sugar control and reduced carbohydrate cravings. Chromium may assist in balancing energy and reducing spikes that lead to fatigue. These ingredients work together to offer synergistic support—helping users feel fuller for longer, more energized, and better equipped to make mindful eating Is Nixol For? Nixol is suitable for adult men and women who are: Looking for natural weight management support Struggling with low energy or poor digestion Interested in non-GMO and vegan-friendly supplements Seeking a gentle alternative to extreme diet pills Focused on long-term wellness over short-term fads Whether someone is starting a new fitness journey or simply wants to support their metabolism as they age, Nixol is designed to fit any lifestyle without requiring major lifestyle changes. Visit Nixol Official Website To Read More.. Trusted Manufacturing and Clean Label Promise All Nixol capsules are made in GMP-certified facilities to ensure safety and consistency. The company proudly avoids artificial fillers, synthetic preservatives, or questionable ingredients. The clean-label transparency ensures users know exactly what they're putting in their bodies—supporting trust and confidence in daily use. How to Use Nixol For Weight Loss Management Taking Nixol is as simple as adding one capsule to your morning routine. There's no need for timing it around meals or pairing it with complicated diet programs. For best results, the product is intended to be taken consistently over time while maintaining a generally healthy lifestyle. Hydration, light physical activity, and sleep hygiene can further enhance the benefits of any wellness supplement—including Nixol. The Bigger Picture: Supporting Confidence and Balance While weight management is often a numbers game in the media, Nixol approaches it differently. The goal is not to chase unrealistic ideals but to support real people in feeling better—physically and mentally. That might mean feeling confident in your own skin, having enough energy to enjoy time with loved ones, or simply ending the day with a calm digestive system. Nixol believes wellness should be achievable, empowering, and natural—and that's exactly the experience it aims to deliver. visit the official website here A Final Word In a crowded supplement market, Nixol offers something refreshingly straightforward: a natural tool to support better metabolic balance, digestion, and daily energy—all in one clean capsule. Its arrival in the UK opens up new possibilities for individuals seeking a simpler way to support their health without harsh chemicals or hype. As awareness grows around the importance of gut health, metabolism, and daily consistency, Nixol is positioned to become a trusted companion for thousands pursuing better wellness—one day at a time. Attachment nixol CONTACT: Media Contact: Nixol Health & Wellness Email: support@ Website: Phone: +44 (0)800 123 4567
Yahoo
an hour ago
- Yahoo
The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs
A new weight-loss treatment that can be administered as either a weekly injection or a daily pill has shown promising results in early-stage trials, according to a new study. In one of the trials, 125 adults were assigned to weekly injections of amycretin. Those receiving the 60 milligram dose lost nearly a quarter of their body weight over 36 weeks. This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost 15 per cent of their body weight over a longer 68 week period. Another trial enrolled 144 adults to test the pill version of amycretin. Those who took the 100 milligram daily tablet lost an average of 13.1 percent of their weight over 12 weeks. While jabs like Ozempic, Wegovy and Mounjaro only target the body's GLP-1 receptors, amycretin targets them as well as the amylin receptors, which help regulate blood glucose levels and appetite. The drug helps to prevent overeating and promote feelings of satiety. The findings were published in The Lancet and presented this week at the American Diabetes Association's Scientific Sessions in Chicago. Researchers also reported that the drug appeared to improve participants' blood sugar control, an important marker for those at risk of developing Type 2 diabetes. Novo Nordisk, the Danish pharmaceutical company behind amycretin — and also the maker of Wegovy and Ozempic — hopes the pill version of amycretin could make weight-loss therapy more accessible, especially in Britain, where around 1.5 million people currently receive weight-loss treatments, mostly as injections prescribed through specialised clinics or by private providers. Pill formulations may simplify prescribing and make long-term weight-loss support easier to scale up. Unlike drugs like Ozempic, amycretin tablets would not need to be refrigerated and do not require syringes. However, amycretin remains in the early stages of clinical testing and that larger trials will be required to fully establish its safety and efficacy. Both forms of the drug were also associated with improvements in blood sugar levels. Patients did report side effects, including nausea and vomiting, but researchers said that they tended to resolve as the treatment progressed.
Health Line
2 hours ago
- Health Line
Intermittent Fasting May Be as Effective as Calorie Restriction for Weight Loss
Intermittent fasting resulted in similar weight loss as traditional calorie restriction, according to a new review. One form of intermittent fasting, known as whole-day fasting, did yield slightly more weight loss than caloric restriction. Experts say that the similar results across different diet protocols mean individuals trying to lose weight have more options available to suit their lifestyle. New research suggests that intermittent fasting is as effective as calorie-restricted diets for weight loss and cardiometabolic risk factors. A systematic review of nearly 100 randomized clinical trials involving intermittent fasting (IF) and traditional calorie restriction (CR) found that both approaches yielded similar health benefits. The study, published on June 18 in The BMJ, found that IF and CR were equally effective. IF involves designated periods of eating and fasting and places less emphasis on what you eat than when you eat. By contrast, CR targets a specific daily calorie goal and allows any eating schedule. The analysis included several of the most common IF protocols, including: Alternate day fasting (ADF) alternates standard eating days with fasting days or very low calorie days. Time-restricted eating (TRE) restricts food intake to a daily window, typically 8 or 12 hours. Whole day fasting, also known as the 5:2 diet, involves two or three weekly fasting days. All forms of IF and traditional CR produced weight loss compared with no intervention at all — known as an ad libitum, or unrestricted, diet. Of the three primary IF methods, only alternate day fasting resulted in greater weight loss than CR. However, the authors note that longer trials are needed to substantiate their findings. 'This analysis suggests that all three approaches, for the most part, lead to similar weight losses. This is why many of us believe that the best approach to losing weight is finding an approach that matches your lifestyle and is something you can practice for the long term,' said David B. Sarwer, PhD, director of the Center for Obesity Research and Education at Temple University and a spokesperson for the Obesity Society. Sarwer wasn't involved in the research. IF has grown rapidly in popularity over the past decade, but evidence of its health benefits — namely, weight loss and cardiometabolic measures, such as blood glucose — has been inconsistent compared with more traditional, calorie-restricted diets. Although proponents of IF may be disappointed by the latest findings, experts say that similar results across diets mean that people have more options to find a method that works best for them. No clear 'best' when it comes to diet protocols Researchers included 99 randomized clinical trials involving more than 6,500 adults in the systematic review. The average age of participants was 45, and two-thirds were women. A small percentage was considered healthy, but the vast majority (about 90%) had existing health conditions, including overweight, obesity, and both type 1 and type 2 diabetes. Participants' average BMI was 31, meeting the standard clinical definition of obesity, which is a body mass index (BMI of 30 or higher. Trials ranged between 3 and 52 weeks — with an average of 12 weeks — and varied in quality. The review found that both IF and CR led to small reductions in body weight compared to an unrestricted diet. Among the different IF protocols, only ADF resulted in slightly more weight loss (nearly three pounds) than CR. Sarwer pointed out that while this may be statistically significant, such additional weight loss would be trivial in improving weight-related health issues. ADF also slightly outperformed both TRE and whole-day fasting in terms of weight loss, but these findings were not deemed significant. ADF also resulted in slight improvements to total and LDL cholesterol compared to time-restricted eating. 'There is no compelling evidence that there is a 'best' diet for weight loss,' said Sarwer. 'Rather, the 'best' approach is one where the person can make small, yet impactful changes to their food choices, eating behaviors, and level of physical activity that cause minimal disruption to their lifestyle and that they can maintain for the long term,' he said. Who benefits from intermittent fasting? Though IF is touted as the diet du jour, there isn't enough compelling evidence to support it yet. Nonetheless, it has been linked to an array of health benefits, including: weight loss improved insulin resistance reduced inflammation brain health The key question, though, is not whether IF is beneficial compared to an unrestricted diet, but whether it's better than CR. That's where things are a little unclear. A 2024 review found that IF and CR were both associated with weight loss and equally effective across cardiometabolic, cancer, and neurocognitive outcomes. However, they noted that IF studies reported greater adherence, meaning people were better able to stick to them for the trial duration. A slightly older study published in NEJM in 2022 also concluded that among people with obesity, TRE wasn't more beneficial than CR. On the other hand, in a clinical trial funded by the NIH, the results of which were published in April 2025, participants who did a variation of whole-day fasting (a 4:3 schedule rather than the more common 5:2) lost 50% more weight than CR (7.6% vs 5% body weight) after one year. The additional weight loss also translated into cardiometabolic improvements, such as blood pressure, total cholesterol, and A1C. Another trial, published in May 2025, found that just three months of TRE led to long-term weight loss, even after participants stopped the protocol. CR isn't perfect either. Though it's long been a standard dietary intervention, it can be harmful, leading to fatigue, nutrient deficiencies, and even depression. For now, experts agree that the right diet solution comes down to the individual. The best diet for you is the one you can stick to. 'Fasting diets are easier to follow because the rules are fairly simple vs trying to start a Mediterranean diet, for example. Some patients who may particularly benefit from a time-restricted diet, for example, are individuals who tend to snack a lot at night,' said Sun Kim, MD, an associate professor of Endocrinology, Gerontology, and Metabolism at Stanford Medicine who wasn't involved in the research. She also cautions that individuals with diabetes who take insulin should be careful with fasting diets, as they may necessitate adjustments to insulin dosage and scheduling. You should also be cautious with intermittent fasting if you: are over age 65 have a history of disordered eating have low blood pressure are pregnant or nursing Adherence is key to long-term weight loss One final notable finding of the study was that adherence rates dropped precipitously the longer trials went on. Studies shorter than 24 weeks had high adherence, above 80%, while trials longer than 52 weeks typically reported poor adherence. In one trial involving whole-day fasting, adherence crashed from 74% at six weeks to just 22% at 52 weeks. These findings reinforce the idea that diet protocols should not be viewed as 'one size fits all' but rather as tailored to each individual's lifestyle. 'I wish there was an easy solution to weight loss. In our society, there are many forces that push individuals toward weight gain. I always discuss with patients about finding a lifestyle change that they can sustain for the long haul,' said Kim. According to Sarwer, small, sustainable changes are key. 'I'm more likely to suggest that people reduce the number of days a week that they eat ice cream, or reduce the portion size they eat, than to recommend that they stop eating ice cream all together,' he said.
